USP and Public Policy
Left
Refine Your Search
USP comments submitted to FDA for Docket No. FDA-2019-N-1845: Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain. Comments…
Learn More
USP Comments submitted to FDA on Continuous Manufacturing for Docket No. FDA-2017-N-2697 for “Submission of Proposed Recommendations for Industry on Developing Continuous Manufacturing of Solid…
Learn More
USP Comments to FDA Public Meeting: “The Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” Regarding Generic Medicines. Comments were submitted 7-18-2017.
Learn More
Submitted August 18, 2023 to Senators Sanders and Cassidy and Representatives McMorris-Rodgers and Pallone regarding the Request for Information Regarding the Food and Drug Administration Regulation…
Learn More
USP appreciates the opportunity to provide comments for the National Conference on Weights and Measures’ (NCWM) consideration on proposed commercial measurement standards for cannabis and cannabis-…
Learn More
The United States Pharmacopeia (USP) is pleased to support the “Mapping America’s Pharmaceutical Supply Act” (H.R. 6992), or the MAPS Act.
Learn More
101 signatures, including USP, wrote to express the collective strong desire to see the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorized before the end of the calendar year in the same…
Learn More
USP is pleased to provide a response to the bicameral Request for Information (RFI) on the increase in drug shortages. Submitted July 7, 2023.
Learn More
The United States Pharmacopeia (USP) is pleased to offer its support for the “Mapping America’s Pharmaceutical Supply Act” (S. 2364), or the MAPS Act.
Learn More
USP is pleased to submit feedback to the Senate HELP Committee on the bipartisan discussion draft to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA).
Learn More